Ftse Mib
36.267,63
1,25%
DAX
20.903,39
1,31%
S&P 500
5.996,66
1,00%
NASDAQ
19.630,20
1,51%
Bitcoin
101.496,92
0,49%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Replimune Group Inc (REPL) Replimune Group Inc (REPL) Notizie

Replimune Group Inc

REPL
10,14
-0,22 (-2,12%)
18 Gen 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
17/1/202523:01EDGAR2Form S-8 - Securities to be offered to employees in employee..
10/1/202522:01GLOBEReplimune Announces Inducement Grants Under Nasdaq Listing..
08/1/202514:00GLOBEReplimune Announces RP2 Development Program Advances with..
23/12/202414:00GLOBEReplimune to Present at the 43rd Annual J.P. Morgan..
20/12/202423:00EDGAR2Form S-8 - Securities to be offered to employees in employee..
19/12/202403:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202422:48EDGAR2Form 144 - Report of proposed sale of securities
04/12/202414:30EDGAR2Form 8-K/A - Current report: [Amend]
27/11/202414:30EDGAR2Form 8-K - Current report
26/11/202423:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
26/11/202414:30EDGAR2Form 8-K - Current report
26/11/202405:55GLOBEReplimune Announces Pricing of Upsized Public Offering
25/11/202413:09GLOBEReplimune Announces Proposed Public Offering
21/11/202423:26EDGAR2Form 8-K - Current report
21/11/202422:05GLOBEReplimune Receives Breakthrough Therapy Designation for RP1..
21/11/202403:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202403:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/11/202423:16EDGAR2Form S-8 - Securities to be offered to employees in employee..
14/11/202413:00EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
12/11/202414:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/11/202414:00GLOBEReplimune Reports Fiscal Second Quarter 2025 Financial..
09/11/202419:00GLOBEReplimune Presents Late-Breaking Abstract Featuring Data..
08/11/202422:01GLOBEReplimune Announces Inducement Grants Under Nasdaq Listing..
30/10/202414:15GLOBEReplimune to Present at the 39th Annual Meeting of the..
16/10/202423:15EDGAR2Form S-8 - Securities to be offered to employees in employee..
09/10/202422:01GLOBEReplimune Announces Inducement Grants Under Nasdaq Listing..
01/10/202414:00GLOBEReplimune to Present at Two Upcoming Investor Conferences
15/9/202415:45GLOBEReplimune Presents Primary Analysis Data from IGNYTE..
09/9/202414:00GLOBEReplimune Announces Positive Pre-BLA Meeting with FDA and..
05/9/202422:05EDGAR2Form 8-K - Current report
05/9/202414:00GLOBEStockholders Vote to Elect Madhavan Balachandran to Board of..
22/8/202414:00GLOBEReplimune Announces Late-Breaking Abstract of IGNYTE..
20/8/202402:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/8/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
13/8/202414:00GLOBEReplimune Announces First Patient Dosed in IGNYTE-3 Clinical..
08/8/202414:45EDGAR2Form S-3 - Registration statement under Securities Act of..
08/8/202414:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202414:04EDGAR2Form 8-K - Current report
08/8/202414:00GLOBEReplimune Reports Fiscal First Quarter 2025 Financial..
30/7/202422:01GLOBEReplimune to Present at Two Upcoming Investor Conferences
19/7/202422:15EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
19/7/202422:15EDGAR2Form DEF 14A - Other definitive proxy statements
13/6/202414:36EDGAR2Form 8-K - Current report
13/6/202414:30GLOBEReplimune Announces $100 Million Private Placement Financing
11/6/202402:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/6/202422:51EDGAR2Form 144 - Report of proposed sale of securities
07/6/202414:00GLOBEReplimune to Present at the Goldman Sachs 45th Annual Global..
06/6/202415:15EDGAR2Form 8-K - Current report
06/6/202413:00GLOBEReplimune Announces Positive Topline Primary Analysis Data..
03/6/202415:27EDGAR2Form 8-K - Current report
Apertura: 10,48 Min: 10,05 Max: 10,48
Chiusura: 10,36

La tua Cronologia

NASDAQ
REPL
Replimune
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network